NASDAQ:ALXO ALX Oncology Q3 2026 Earnings Date & Estimates $1.25 +0.07 (+5.93%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.20 -0.05 (-4.00%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ALX Oncology is scheduled to report Q3 2026 earnings on Friday, November 6, 2026. The conference call is scheduled for 8:30 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 6, 2026Conference Call8:30 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from ALX Oncology in Q3 2026ALX Oncology is expected to post earnings of -$0.15 per share. In the same quarter a year earlier ALX Oncology reported -$0.41 per share. ALX Oncology last reported on August 6, 2026, posting -$0.13 per share and beating the -$0.1429 consensus estimate. ALX Oncology has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.15Prior-Year EPS-$0.41Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.13 (Beat by +$0.0129)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report ALX Oncology Q3 2026 Earnings FAQ When does ALX Oncology report Q3 2026 earnings? ALX Oncology (NASDAQ:ALXO) is scheduled to report Q3 2026 earnings on Friday, November 6, 2026. What time is ALX Oncology's Q3 2026 earnings call? ALX Oncology's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for ALX Oncology? Analysts expect ALX Oncology to post earnings of -$0.15 per share for Q3 2026. ALX Oncology Earnings HeadlinesALX Oncology Holdings Inc. (NASDAQ:ALXO) Stock Rated "Moderate Buy" by Sell-Side BrokeragesOctober 4, 2026 | americanbankingnews.comAlx Oncology Holdings (ALXO)September 30, 2026 | in.investing.comI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called to our community before the big move happened… And right now, I'm making my next big call. It's a coin trading under $1.00… one most investors have never even heard of. But the world's largest bank is already building on it. It has a burn mechanism wired directly to institutional usage… meaning the more the big money uses it, the more rare it becomes. And its biggest supply cut in history happened earlier this year… | Crypto 101 Media (Ad)ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2 ...September 28, 2026 | finance.yahoo.comAlx Oncology Holdings Inc. Announces Nature Medicine Publication of Aspen-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept ...September 28, 2026 | marketscreener.comMALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric CancerSeptember 28, 2026 | globenewswire.comSee More ALX Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ALX Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ALX Oncology and other key companies, straight to your email. Email Address About ALX OncologyALX Oncology (NASDAQ:ALXO) is a clinical-stage biopharmaceutical company focused on developing therapies that activate the immune system to fight cancer. The company’s research is centered on the CD47-SIRPα pathway, an innate immune checkpoint that cancer cells can use to avoid detection and destruction by immune cells. Its lead investigational product is evorpacept, also known as ALX148, a protein therapeutic designed to block CD47 while limiting binding to red blood cells. Evorpacept is being evaluated in combination with other cancer treatments across several potential indications, including hematologic malignancies and solid tumors. The company’s programs remain investigational and are subject to clinical and regulatory outcomes. ALX Oncology was founded in 2015 and is headquartered in the San Francisco Bay Area of California. The company’s development activities are primarily focused on oncology research and clinical trials conducted with medical and research partners in the United States and internationally. Jaideep Dudell has served as the company’s president and chief executive officer.View ALX Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueMicrosoft Is Almost Back to $555—Now the Hard Part BeginsSkydance Just Became a Media Giant—With an $80 Billion Debt Load Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
